163 related articles for article (PubMed ID: 24575739)
21. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Pignochino Y; Capozzi F; D'Ambrosio L; Dell'Aglio C; Basiricò M; Canta M; Lorenzato A; Vignolo Lutati F; Aliberti S; Palesandro E; Boccone P; Galizia D; Miano S; Chiabotto G; Napione L; Gammaitoni L; Sangiolo D; Benassi MS; Pasini B; Chiorino G; Aglietta M; Grignani G
Mol Cancer; 2017 Apr; 16(1):86. PubMed ID: 28454547
[TBL] [Abstract][Full Text] [Related]
22. Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.
Yoon C; Chang KK; Lee JH; Tap WD; Hart CP; Simon MC; Yoon SS
Oncotarget; 2016 Jul; 7(28):42844-42858. PubMed ID: 27374091
[TBL] [Abstract][Full Text] [Related]
23. Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells.
Roepke M; Diestel A; Bajbouj K; Walluscheck D; Schonfeld P; Roessner A; Schneider-Stock R; Gali-Muhtasib H
Cancer Biol Ther; 2007 Feb; 6(2):160-9. PubMed ID: 17218778
[TBL] [Abstract][Full Text] [Related]
24. Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies.
Rouleau C; Gianolio DA; Smale R; Roth SD; Krumbholz R; Harper J; Munroe KJ; Green TL; Horten BC; Schmid SM; Teicher BA
Mol Cancer Ther; 2015 Sep; 14(9):2081-9. PubMed ID: 26184481
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
[TBL] [Abstract][Full Text] [Related]
26. NVP-BEZ235 as a new therapeutic option for sarcomas.
Manara MC; Nicoletti G; Zambelli D; Ventura S; Guerzoni C; Landuzzi L; Lollini PL; Maira SM; García-Echeverría C; Mercuri M; Picci P; Scotlandi K
Clin Cancer Res; 2010 Jan; 16(2):530-40. PubMed ID: 20068094
[TBL] [Abstract][Full Text] [Related]
27. The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.
Bid HK; Phelps DA; Xaio L; Guttridge DC; Lin J; London C; Baker LH; Mo X; Houghton PJ
Mol Cancer Ther; 2016 May; 15(5):1018-28. PubMed ID: 26908627
[TBL] [Abstract][Full Text] [Related]
28. Ethyl-2-amino-pyrrole-3-carboxylates are novel potent anticancer agents that affect tubulin polymerization, induce G2/M cell-cycle arrest, and effectively inhibit soft tissue cancer cell growth in vitro.
Boichuk S; Galembikova A; Zykova S; Ramazanov B; Khusnutdinov R; Dunaev P; Khaibullina S; Lombardi V
Anticancer Drugs; 2016 Aug; 27(7):620-34. PubMed ID: 27129079
[TBL] [Abstract][Full Text] [Related]
29. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines.
Fujii H; Honoki K; Tsujiuchi T; Kido A; Yoshitani K; Takakura Y
Int J Oncol; 2009 May; 34(5):1381-6. PubMed ID: 19360350
[TBL] [Abstract][Full Text] [Related]
30. Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug.
Garofalo C; Capristo M; Manara MC; Mancarella C; Landuzzi L; Belfiore A; Lollini PL; Picci P; Scotlandi K
PLoS One; 2013; 8(12):e83832. PubMed ID: 24391834
[TBL] [Abstract][Full Text] [Related]
31. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
[TBL] [Abstract][Full Text] [Related]
32. Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines.
Mayer F; Mueller S; Malenke E; Kuczyk M; Hartmann JT; Bokemeyer C
Invest New Drugs; 2005 Jun; 23(3):205-11. PubMed ID: 15868376
[TBL] [Abstract][Full Text] [Related]
33. HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components.
Lopez G; Song Y; Lam R; Ruder D; Creighton CJ; Bid HK; Bill KL; Bolshakov S; Zhang X; Lev D; Pollock RE
Mol Cancer Res; 2016 Jan; 14(1):35-43. PubMed ID: 26396249
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines.
Yang C; Choy E; Hornicek FJ; Wood KB; Schwab JH; Liu X; Mankin H; Duan Z
Anticancer Res; 2011 Apr; 31(4):1115-23. PubMed ID: 21508354
[TBL] [Abstract][Full Text] [Related]
35. A synthetic cantharidin analog for the enhancement of doxorubicin suppression of stem cell-derived aggressive sarcoma.
Zhang C; Peng Y; Wang F; Tan X; Liu N; Fan S; Wang D; Zhang L; Liu D; Wang T; Wang S; Zhou Y; Su Y; Cheng T; Zhuang Z; Shi C
Biomaterials; 2010 Dec; 31(36):9535-43. PubMed ID: 20875681
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
Scotlandi K; Manara MC; Nicoletti G; Lollini PL; Lukas S; Benini S; Croci S; Perdichizzi S; Zambelli D; Serra M; García-Echeverría C; Hofmann F; Picci P
Cancer Res; 2005 May; 65(9):3868-76. PubMed ID: 15867386
[TBL] [Abstract][Full Text] [Related]
37. Arsenic trioxide inhibits the growth of adriamycin resistant osteosarcoma cells through inducing apoptosis.
Zhao H; Guo W; Peng C; Ji T; Lu X
Mol Biol Rep; 2010 Jun; 37(5):2509-15. PubMed ID: 19701692
[TBL] [Abstract][Full Text] [Related]
38. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
Merchant MS; Woo CW; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
Anderson JL; Park A; Akiyama R; Tap WD; Denny CT; Federman N
PLoS One; 2015; 10(9):e0133610. PubMed ID: 26402468
[TBL] [Abstract][Full Text] [Related]
40. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma.
Hingorani P; Zhang W; Piperdi S; Pressman L; Lin J; Gorlick R; Kolb EA
Cancer Chemother Pharmacol; 2009 Sep; 64(4):733-40. PubMed ID: 19224214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
